Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells

Chimeric antigen receptor T-cell (CAR-T) therapy targeted against B-cell maturation antigen (BCMA) in multiple myeloma (MM) has produced rapid responses but many eventually relapse. In light of this new treatment, novel predictors of progression-free survival (PFS) are needed. We performed a single...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Sandy W., Shah, Nina, Ledergor, Guy, Martin, Thomas, Wolf, Jeffrey, Shui, Amy M., Huang, Chiung-Yu, Martinez-Lopez, Joaquin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685203/
https://www.ncbi.nlm.nih.gov/pubmed/34938662
http://dx.doi.org/10.3389/fonc.2021.783703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685203/
https://www.ncbi.nlm.nih.gov/pubmed/34938662
http://dx.doi.org/10.3389/fonc.2021.783703

Ejemplares similares